Regentis Biomaterials Ltd. Stock Price

NYSEAM:RGNT Community·US$20.2m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create Narrative

RGNT Share Price Performance

US$3.77

-3.73 (-49.73%)

US$3.77

-3.73 (-49.73%)

US$3.77

Tue, 30 Jun 26

Share Pricen/a

RGNT Community Narratives

There are no narratives available yet.

Create Narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

0 Rewards

View Full Analysis

Regentis Biomaterials Ltd. Key Details

Last Reported Earnings

Dec 31, 2025

Next Reporting Earnings

n/a

: -2.64
: 0%
: 0%
: 25.2%

View Full Analysis

About RGNT

Founded: 2004
Employees: n/a
CEO: Ehud Geller
WebsiteView website: www.regentis.co.il

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.